Showing results (11-20 of 426) with videos related to
Sort By:
Pageof 43
Heart (British Cardiac Society)|October 26, 2022
Inflammatory and thrombotic valvulopathies in autoimmune diseaseYevgeniya Gartshteyn, Nicole Bhave, Megan Shetty Joseph, et al.Expert Review of Clinical Immunology|December 11, 2023
SLE criteria are by necessity still based on clinical (and immunological) criteria itemsMartin Aringer, Marta MoscaClinical Drug Investigation|October 4, 2023
Acthar® Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical EvidenceJeffrey Kaplan, Anca Askanase, David Chu, et al.Lupus Science & Medicine|July 20, 2019
Prevalence of coronary artery calcification in young patients with SLE of predominantly Hispanic and African-American descentYevgeniya Gartshteyn, Genna Braverman, Sharan Mahtani, et al.Best Practice & Research. Clinical Rheumatology|December 12, 2017
Treat to target, remission and low disease activity in SLEEric F Morand, Marta MoscaClinical and Experimental Rheumatology|October 17, 2013
New drugs in systemic lupus erythematosus: when to start and when to stopMarta Mosca, Ronald van VollenhovenCurrent Rheumatology Reports|November 12, 2021
The Use of COVID-19 Vaccines in Patients with SLEWei Tang, Yevgeniya Gartshteyn, Edd Ricker, et al.Clinical and Experimental Rheumatology|October 17, 2013
Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal?Marta Mosca, Chiara Tani, Martin AringerExpert Opinion on Pharmacotherapy|April 12, 2007
LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosusMarta Mosca, Chiara Baldini, Stefano BombardieriBest Practice & Research. Clinical Rheumatology|September 10, 2005
Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indicesBridget Griffiths, Marta Mosca, Caroline GordonPageof 43